M Kůta
Impact in
-
- Lung Cancer Research Studies
- Cancer-related Molecular Pathways
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 5
- Cancer Treatment and Pharmacology 2
- Lung Cancer Research Studies 2
-
- Lung Cancer Treatments and Mutations 3
- Advanced Breast Cancer Therapies 1
- Lung Cancer Diagnosis and Treatment 1
- Co-authors
- Petr Zatloukal (3 shared papers)Jaromı́r Roubec (3 shared papers)Adrie Gunther (2 shared papers)Setareh Shamsili (2 shared papers)Rob J. van Klaveren (1 shared paper)Giuseppe Giaccone (2 shared papers)Karijn Floor (1 shared paper)Luboš Petruželka (3 shared papers)
- Journals
- Molecular Cancer Therapeutics (1 paper)Journal of Clinical Oncology (1 paper)Annals of Oncology (1 paper)Lung Cancer (1 paper)PubMed (1 paper)
- Partner nations
- CzechiaSpainPalestinian Territory
In The Last Decade
M Kůta
4 papers receiving 371 citations
Peers
Comparison fields: 5 of 57
- Oncology 224
- Pulmonary and Respiratory Medicine 152
- Cancer Research 47
- Molecular Biology 205
- Toxicology 6
Countries citing papers authored by M Kůta
This map shows the geographic impact of M Kůta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Kůta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Kůta more than expected).
Fields of papers citing papers by M Kůta
This network shows the impact of papers produced by M Kůta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Kůta. The network helps show where M Kůta may publish in the future.
Co-authors
The 25 scholars most cited alongside M Kůta, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 210 | |
| 2 | 2003 | 139 | |
| 3 | 2003 | 30 | |
| 4 | A phase II, monotherapy study of YM155, a novel survivin suppressant, in previously treated advanced stage non-small cell lung cancer (NSCLC) | 2007 | 2 |
| 5 | [Comparison of adjuvant chemotherapy in breast carcinoma with a combination of cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and AC (doxorubicin, cyclophosphamide). Initial results of a national cooperative study]. | 1998 | 1 |
About M Kůta
M Kůta is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Epidemiology and Genetics, having authored 5 papers that have together received 382 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (3 papers), Cancer Treatment and Pharmacology (2 papers), Lung Cancer Research Studies (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (1 paper), Advanced Breast Cancer Therapies (1 paper), Lung Cancer Diagnosis and Treatment (1 paper), Estrogen and related hormone effects (1 paper) and Cell death mechanisms and regulation (1 paper). The work is most often cited by research in Oncology (224 citations), Pulmonary and Respiratory Medicine (152 citations), Cancer Research (47 citations), Molecular Biology (205 citations) and Toxicology (6 citations). M Kůta has collaborated with scholars based in Czechia, Spain and Palestinian Territory. Frequent co-authors include Petr Zatloukal, Jaromı́r Roubec, Adrie Gunther, Setareh Shamsili, Rob J. van Klaveren, Giuseppe Giaccone, Karijn Floor, Luboš Petruželka, Tomáš Skácel and Vı́tězslav Kolek. Their work appears in journals such as Molecular Cancer Therapeutics, Journal of Clinical Oncology, Annals of Oncology, Lung Cancer and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.